



Society for Melanoma Research

<http://www.societymelanomaresearch.org>

Agenda

Second International Melanoma Research Congress

FROM BENCH TO BEDSIDE

Pointe Hilton at Squaw Peak
Phoenix, Arizona
November 13-16, 2004

Conference Co-Chairs

Menashe Bar-Eli, PhD
M.D. Anderson Cancer Center
Houston, TX

Vernon K. Sondak, MD
H. Lee Moffitt Cancer Center
Tampa, FL

Deadline for Abstracts: August 1, 2004

Saturday, November 13

3:00 pm to 10:00 pm REGISTRATION

7:00 pm to 9:00 pm KEYNOTE ADDRESSES

**Meenhard Herlyn, DVM, DSc, The Wistar Institute,
Philadelphia, PA**

“Targeting Signaling Pathways for Melanocyte Transformation and
Melanoma Therapy”

**Lynn Schuchter, MD, University of Pennsylvania, Philadelphia,
PA**

“Are We at a Turning Point for Melanoma Therapy?”

9:00 pm to 10:00 pm OPENING RECEPTION

Sunday, November 14

**7:30 am to 8:30 am Welcoming Remarks and Introduction to the Congress
Charles M. Balch, MD, Professor of Surgery and Oncology,
Johns Hopkins Medical Inst., Baltimore, MD, and American
Society for Clinical Oncology, Alexandria, VA**
“The Future of Melanoma Diagnosis, Staging and Multi-disciplinary
Treatment”

**8:00 am to 10:00 am Session 1, New Approaches to Understanding and Treating
Melanoma**

**Jeffrey M. Trent, PhD, Translational Genomics Research
Institute, Phoenix, AZ
Chair**

8:00-8:10 am	Introduction - Chair
8:10-8:30 am	Paul Meltzer, MD, PhD, National Human Genome Research Institute, Bethesda, MD “Applications of Genomic Profiling To Melanoma”
8:35-8:55 am	Francesco M. Marincola, MD, National Cancer Institute, Bethesda, MD “The Tumor Microenvironment as a Modulator of Anti-Cancer Immune Responses”
9:00-9:20 am	David Evans, PhD, Translational Genomics Research Institute, Phoenix, AZ “High Throughput Functional Chemogenomics for Cancer Drug Discovery”
9:25-9:35 am	Proffered abstract
9:40-10:00 am	Svetomir Markovic, MD, PhD, The Mayo Clinic, Rochester, MN “Aerosolized GM-CSF Immunotherapy for Metastatic Melanoma”
10:05-10:30 am	Break
10:30 am to 12:30 pm	Session 2, Genomics and Proteomics of Melanoma Daniel Pinkel, PhD, UCSF Comprehensive Cancer Center, San Francisco, CA Chair
10:30-10:40 am	Introduction – Chair
10:40-11:00 am	Ashani Weeraratna, PhD, National Institute of Aging, Baltimore, MD “Unraveling The Mechanisms of Melanoma Progression: From Profiles to Pathways and Back Again”
11:05-11:25 am	Katherine Resing, PhD, University of Colorado, Boulder, CO “Protein Profiling in Human Melanoma Cell Lines by Shotgun Proteomics”
11:30-11:50 am	Glenn Merlino, PhD, National Cancer Institute, Bethesda, MD “Molecular Pathology of Melanoma: Perspective from the Mouse”
11:55 am-12:05 pm	Proffered abstract
12:10-12:30 pm	Boris C. Bastian, MD, UCSF Comprehensive Cancer Center, San Francisco, CA “Genomics of Primary Cutaneous Melanoma”
12:35-2:00 pm	Break
2:00 pm to 4:00 pm	Session 3 (Parallel Session 1A), Staging and Clinical Trials of Melanoma

**Vernon Sondak, H. Lee Moffitt Cancer Center, Tampa, FL
Chair**

- 2:00-2:10 pm Introduction - Chair
- 2:10-2:30 pm Vernon K. Sondak, MD, H. Lee Moffitt Cancer Center, Tampa, FL
"Who Should Undergo Sentinel Node Biopsy: Frontiers in the Staging of Melanoma?"
- 2:35-2:55 pm Alistair J. Cochran, MD, UCLA School of Medicine, Los Angeles, CA
"Pathobiology of the Sentinel Node"
- 3:00-3:20 pm Walter Urba, MD, PhD, Earle A. Chiles Research Institute, Portland, OR
"Evaluating Melanoma-Specific Immune Responses in Sentinel Lymph Node Biopsies"
- 3:25-3:35 pm Proffered abstract
- 3:40-4:00 pm Kelly McMasters, MD, PhD, University of Louisville, Louisville, KY
"Clinical Trials of Sentinel Lymph Node Biopsy for Melanoma"

**2:00 pm to 4:00 pm Session 4 (Parallel Session 1B), Melanocyte Development and Biology
Vincent J. Hearing, PhD, National Cancer Institute, Bethesda, MD
Chair**

- 2:00-2:10 pm Introduction – Chair
- 2:10-2:30 pm Richard A. Sturm, PhD, The University of Queensland, Brisbane, Australia
"Regulation of Melanocyte Development, Differentiation and Transformation by the Transcription Factor BRN2"
- 2:35-2:55 pm Dorothy C. Bennett, MA, PhD, St. George's Hospital Medical School, London, UK
"Melanocyte Immortalization and Melanoma Initiation"
- 3:00-3:20 pm Ze'ev Ronai, PhD, Mount Sinai School of Medicine, New York, NY
"Novel Aspects in Understanding ATF2 as a Marker and a Target in Melanoma"
- 3:25-3:35 pm Proffered abstract
- 3:40-4:00 pm David E. Fisher, MD, PhD, Dana Farber Cancer Institute, Boston, MA
"The MITF Transcription Factor Family in Melanocytes and Cancer"
- 4:30 pm to 6:00 pm Poster Session A. Biology, Epidemiology, and Genetics.**

Monday, November 15

- 8:00 am to 10:00 am Session 5, Immunobiology and Immunotherapy of Melanoma**

**Giorgio Parmiani, MD, Istituto Nazionale Tumori, Milan, Italy
Chair**

8:00-8:10 am	Introduction - Chair
8:10-8:30 am	Bernard A. Fox, PhD, Earle A. Chiles Res. Inst., Portland, OR "T Cell-Mediated Tumor Regression: How It Works and How It Can be Augmented"
8:35-8:55 am	Yutaka Kawakami, MD, PhD, Keio University School of Medicine, Tokyo, Japan "Immunogenicity of Various Human Melanoma Antigens Identified by Immunological and Genetic Methods"
9:00-9:20 am	Licia Rivoltini, MD, Istituto Nazionale Tumori, Milan, Italy "Immunomodulatory Effects of Melanoma-Released Microvesicles"
9:25-9:35 am	Proffered abstract
9:40-10:00 am	Patrick Hwu, MD, M.D. Anderson Cancer Center, Houston, TX "Treatment of Melanoma with T Cells and Dendritic Cells"
10:05-10:30 am	Break
10:30 am to 12:30 pm	Session 6 (Parallel Session 2A), Genetics of Melanoma David Hogg, MD, University of Toronto, Toronto, Canada Chair
10:30-10:40 am	Introduction - Chair
10:40-11:00 am	Ron Agatep, PhD, University of Toronto, Toronto, Canada "Novel Interacting Partners of p16 ^{INK4A} "
11:05-11:25 am	Richard Marais, PhD, The Institute of Cancer Research, London, UK "B-Raf is an Oncogene and Therapeutic Target in Melanoma"
11:30-11:50 am	Graham J. Mann, PhD, University of Sydney, Westmead, Australia "Alternative Pathways of p16 ^{INK4A} Action"
11:55 am-12:05 pm	Proffered abstract
12:10-12:30 pm	Nelleke A. Gruis, PhD, Leiden University Medical Center, Leiden, The Netherlands "Genetic and Clinical Aspects of Familial Melanoma"
10:30 am to 12:30 pm	Session 7 (Parallel Session 2B), Biomarkers of Melanoma Dirk J. Ruiter, MD, PhD, UMC St. Radboud, Nijmegen, The Netherlands Chair
10:30-10:40 am	Introduction – Chair

10:40-11:00 am	Robert M. W. De Waal, PhD, UMC St. Radboud, Nijmegen, The Netherlands “Melanoma Vascularity and the Mechanism of Metastasis”
11:05-11:25 am	Natalie Ahn, PhD, HHMI, University of Colorado, Boulder, CO “Functional Proteomics of Melanoma Progression”
11:30-11:50 am	David E. Elder, MB, ChB, University of Pennsylvania, Philadelphia, PA “Markers of Tumor Progression, Diagnosis and Prognosis in Melanoma”
11:55 am-12:05 pm	Proffered abstract
12:10-12:30 pm	Scott Saxman, MD, National Cancer Institute, Bethesda, MD “Clinical Considerations for Molecular Targeting in Melanoma”
12:35-2:00 pm	Lunch and General Meeting of the Society for Melanoma Research (SMR)
2:00 pm to 4:00 pm	Session 8 (Parallel Session 3A), Melanoma Progression and Metastasis Menashe Bar-Eli, PhD, MD Anderson Cancer Center, Houston, TX Chair
2:00-2:10 pm	Introduction - Chair
2:10-2:30 pm	Estela E. Medrano, PhD, Baylor College of Medicine, Houston, TX “The Multiple Roles of SKI in Human Melanoma Progression”
2:35-2:55 pm	Dorothea Becker, PhD, University of Pittsburgh, Pittsburgh, PA “Analysis of Novel Genes Identified in Melanoma and Nevus SAGE Libraries and by Microarrays”
3:00-3:20 pm	Mark A. Nelson, PhD, Arizona Cancer Center, Tucson, AZ “Inhibition of Protein Translation Initiation and Apoptosis in Melanoma Cells”
3:25-3:35 pm	Proffered abstract
3:40-4:00 pm	Jeffrey S. Weber, MD, PhD, Norris Cancer Center, USC, Los Angeles, CA “New Paradigm for Inducing Melanoma Specific Immunity”
2:00 pm to 4:00 pm	Session 9 (Parallel Session 3B), Molecular Epidemiology of Melanoma Marianne Berwick, University of New Mexico, Albuquerque, NM Chair
2:00-2:10 pm	Introduction - Chair
2:10-2:30 pm	Bruce K. Armstrong, MD, PhD, University of Sydney, Sydney, Australia “Interactions of Sun Exposure and Key Genetic Variants in Causing

Cutaneous Melanoma: The Genes, Environment and Melanoma Study”

2:35-2:55 pm

Åke Borg, PhD, University of Lund, Lund, Sweden
“Genetics of Familial Cutaneous and Ocular Malignant Melanoma in Scandinavia”

3:00-3:20 pm

Nicholas K. Hayward, PhD, Queensland Institute of Medical Research, Brisbane, Australia
“Gene-Gene and Gene-Environment Interactions in Conferring Melanoma Risk”

3:25-3:35 pm

Proffered abstract

3:40-4:00 pm

Julia Newton-Bishop, MD, St. James University Hospital, Leeds, UK
“Progress in Understanding High and Low Penetrance Susceptibility Genes for Melanoma”

4:30 pm to 7:00 pm

Poster Session B Immunology and Clinical Investigations

7:30 pm to 10:00 pm

**Reception/Dinner
Awards
Special Lectures**

Tuesday, November 16

8:00 am to 10:00 am

**Session 10, Microenvironment of Melanoma
Mary Hendrix, PhD, Feinberg School of Medicine, Northwestern University, Chicago, IL
Chair**

8:00-8:10 am

Introduction - Chair

8:10-8:30 am

James J. Mulé, PhD, H. Lee Moffitt Cancer Center, Tampa, FL
“Enhancing Dendritic Cell Vaccines for Advanced Melanoma”

8:35-8:55 am

James B. McCarthy, PhD, University of Minnesota Medical School, Minneapolis, MN
“Proteoglycans/Glycosaminoglycans in Melanoma Progression”

9:00-9:20 am

Richard E.B. Seftor, PhD, Feinberg School of Medicine, Northwestern University, Chicago, IL
“The Role of Proteolytically Cleaved Extracellular Matrix Fragments in Melanoma Progression”

9:25-9:35 am

Proffered abstract

9:40-10:00 am

Brian Nickoloff, MD, PhD, Oncology Institute, Maywood, IL
“Role of Notch Signaling in Melanoma Pathogenesis and Treatment”

10:05-10:30 am

Break

10:30 am to 12:30 pm	Session 11, Apoptosis in Melanoma Ze'ev Ronai, PhD, Mount Sinai School of Medicine, New York, NY Chair
10:30-10:40 am	Introduction - Chair
10:40-11:00 am	Ruth Halaban, PhD, Yale University School of Medicine, New Haven, CT "Novel Pathways in the Transformation of Melanocytes to Melanomas"
11:05-11:25 am	Norman Sharpless, MD, University of North Carolina, Chapel Hill, NC "Oncogenomics in Mouse Models of Human Melanomas"
11:30-11:50 am	Liliana Ossowski, PhD, Mount Sinai School of Medicine, New York, NY "Altered Regulation of ERK and p38 Pathways in Melanoma"
11:55 am-12:05 pm	Proffered abstract
12:10-12:30 pm	Jack Arbiser, MD, PhD, Emory University School of Medicine, Atlanta, GA "Melanoma: Many Mutations, Few Pathways"
2:00 pm to 6:30 pm	Workshop on B-Raf: Genetics, Signaling, and Therapy Meenhard Herlyn, DVM, DSc, The Wistar Institute, Philadelphia, PA Chair
2:00-2:20 pm	Martin McMahon , PhD, UCSF Comprehensive Cancer Center, San Francisco, CA "Oncogenic Transformation of Cells by Activated B-Raf"
2:25-2:40 pm	David A. Tuveson, MD, PhD, University of Pennsylvania, Philadelphia, PA "Analysis of Oncogenic B-Raf Function"
2:45-3:10 pm	Gavin P. Robertson, PhD, Penn State College of Medicine, Hershey, PA "V599E B-Raf Regulates the Vascular Development of Melanoma Tumors"
3:15-3:30 pm	Jürgen C. Becker, MD, PhD, Julius Maximilians University, Würzburg, Germany "HLA-B27 Restricted T-Cell Responses to Constitutively Active V599E B-Raf"
3:35-3:55 pm	TBA "New Molecular Targets for the Treatment of Melanoma"
4:00-4:30 pm	Break
4:30-4:55 pm	Deborah Morrison, PhD, National Cancer Institute, Frederick, MD "The Regulation of Signal Transduction Through the Raf/MEK/ERK Pathway"

5:00-5:25 pm

Channing Der, PhD, Lineberger Comprehensive Cancer Center,
Chapel Hill, NC
"Role of Aberrant B-Raf Signaling in Melanoma Growth"

5:30-5:55 pm

Richard Jove, PhD, H. Lee Moffitt Cancer Center, Tampa, FL
"STAT3 Signaling as a New Target for Melanoma Therapy"

6:00-6:30 pm

Summary and Discussion

For more information:

<http://www.societymelanomaresearch.org>